title: Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
abstract: Patients with relapsed diffuse large B-cell lymphoma (DLBCL) who have failed or are ineligible for autologous haematopoietic cell transplantation (HCT) have a poor prognosis. We examined the outcomes of non-myeloablative allogeneic HCT in this setting. Thirty-one patients with DLBCL and one patient with Burkitt lymphoma received allogeneic HCT following 2 Gy total body irradiation with or without fludarabine. Median age was 52 years. Twenty-four patients (75%) had undergone prior autologous HCT. Disease status at HCT was complete response (14/32, 44%), partial response (9/32, 28%), or refractory (9/32, 28%). Cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV, grades III-IV, and chronic GVHD were 53%, 19%, and 47% respectively. With a median follow-up of 45 months, 3-year estimated overall (OS) and progression-free survival (PFS) was 45% and 35% respectively. Three-year cumulative incidences of relapse and non-relapse mortality were 41% and 25% respectively. In multivariate models, chemosensitive disease and receipt of >or=4 lines of treatment before HCT were associated with better OS. Patients with chemosensitive disease had 3-year OS and PFS of 56% and 43% respectively. Non-myeloablative allogeneic HCT can produce long-term disease-free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT.
authors.affiliation: Transplantation Biology Program, Fred Hutchinson Cancer Research Center & University of Washington, Seattle, WA 98109, USA.
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Rezvani
authors.forename: Lalitha
authors.initials: L
authors.lastname: Norasetthada
authors.forename: Ted
authors.initials: T
authors.lastname: Gooley
authors.forename: Mohamed
authors.initials: M
authors.lastname: Sorror
authors.forename: Michelle E
authors.initials: ME
authors.lastname: Bouvier
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Sahebi
authors.forename: Edward
authors.initials: E
authors.lastname: Agura
authors.forename: Thomas
authors.initials: T
authors.lastname: Chauncey
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
authors.forename: Michael
authors.initials: M
authors.lastname: Maris
authors.forename: Judith
authors.initials: J
authors.lastname: Shizuru
authors.forename: Benedetto
authors.initials: B
authors.lastname: Bruno
authors.forename: Christopher
authors.initials: C
authors.lastname: Bredeson
authors.forename: Thoralf
authors.initials: T
authors.lastname: Lange
authors.forename: Andrew
authors.initials: A
authors.lastname: Yeager
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Sandmaier
authors.forename: Rainer F
authors.initials: RF
authors.lastname: Storb
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney